STATEMENT OF NEED/TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials result in the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. To bridge the gap between research and patient care, Breast Cancer Update uses one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the clinical implications of emerging clinical trial data in breast cancer treatment, and incorporate these findings into management strategies in the neoadjuvant, adjuvant and metastatic settings.
• Counsel appropriately selected patients about the availability of ongoing clinical trials.
• Consider key clinical and pathologic risk factors when selecting appropriate regimens for the medical and surgical management of early breast cancer.
• Assess existing data and emerging research focusing on the optimal duration and sequence of adjuvant endocrine therapy in the management of the postmenopausal patient with ER-positive breast cancer, and apply this evidence to routine patient care decisions.
• Implement an algorithm for HER2 testing and selection of evidence-based treatment strategies for early and advanced HER2-positive breast cancer.
• Evaluate the practical application of currently available tissue-based genomic assays to assist with therapeutic decision-making in the management of early breast cancer and, when applicable, use these in the selection of individualized treatment regimens.
• Review the emerging data on various adjuvant chemotherapy approaches, including dose-dense or alternative novel scheduling and the contributory roles of taxanes and anthracyclines, and explain the absolute risks and benefits of these regimens to patients.
• Evaluate the emerging data for novel biologic and molecular-targeted therapies with clinical activity in breast cancer, and determine how these should be incorporated into the treatment algorithm for appropriate patients with metastatic disease.
• Integrate psychosocial support measures, optimal patient-physician communication strategies and evidence-based clinical decision-making into comprehensive oncology care.

PURPOSE OF THIS ISSUE OF BREAST CANCER UPDATE

The purpose of Issue 2 of Breast Cancer Update is to support the learning objectives by offering the perspectives of Drs Albain, Hudis, Jones, Lin, Miller, O’Shaughnessy and Peto on the integration of emerging clinical research data into the management of breast cancer.

ACCREDITATION STATEMENT

The purpose of Issue 2 of Breast Cancer Update is to support the learning objectives by offering the perspectives of Drs Albain, Hudis, Jones, Lin, Miller, O’Shaughnessy and Peto on the integration of emerging clinical research data into the management of breast cancer.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Educational Assessment located at www.BreastCancerUpdate.com/CME. www.BreastCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

---

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Roche Laboratories Inc and Sanofi-Aventis.

.

Home · Search

EDITOR'S NOTE
San Antonio adventure, 2007
Neil Love, MD
- Select publications

INTERVIEWS
Stephen E Jones, MD
- Select publications

Sir Richard Peto, FRS
- Select publications

Kathy S Albain, MD
- Select publications

Roundtable Discussion
- Select publications

Joyce O’Shaughnessy, MD
- Select publications

Nancy U Lin, MD
- Select publications

Breast Cancer Update:
A CME Audio Series and Activity

Editor's Office

Faculty Disclosures